Press Releases May 27, 2026 04:05 PM

BillionToOne to Participate in the William Blair 46th Annual Growth Stock Conference

BillionToOne to present at William Blair 46th Annual Growth Stock Conference

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
BLLN

BillionToOne, Inc., a molecular diagnostics company specializing in DNA counting technology, announced its participation in the William Blair 46th Annual Growth Stock Conference, where management will present upcoming company developments.

BillionToOne to Participate in the William Blair 46th Annual Growth Stock Conference
BLLN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • BillionToOne is showcased at a notable growth stock conference, highlighting its molecular diagnostics platform.
  • The company’s patented Quantitative Counting Templates™ (QCT™) technology enables accurate single-molecule DNA counting.
  • The event presentation is scheduled for June 2, 2026, with a live webcast available to investors.

MENLO PARK, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the William Blair 46th Annual Growth Stock Conference.

Management will present from 12:40pm to 1:10pm Central Time on Tuesday, June 2, 2026.

A live and archived webcast will be available on the “Events & Presentations” page of BillionToOne’s investor relations website at https://investors.billiontoone.com/news-events/events-presentations.

About BillionToOne

Headquartered in Menlo Park, California, BillionToOne is a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level.

Investor Contact
[email protected]

Media Contact
[email protected]


Risks

  • No new product launches or financial updates provided, limiting immediate impact on valuation.
  • Conference participation does not guarantee increased market interest or business growth.
  • Reliance on technological adoption in the molecular diagnostics sector which is competitive and subject to regulatory changes.

More from Press Releases

Kosmos Energy to Host Second Quarter 2026 Results and Webcast on August 3, 2026 Jul 7, 2026 Shell second quarter 2026 update note Jul 7, 2026 Kayan Announces US-Regulated ATS Sets August 3, 2026 Listing Date Jul 6, 2026 Liquidity Services Announces Appointment of new Chief Human Resources Officer Jul 6, 2026 Bleichroeder Acquisition Corp. III Announces the Pricing of $300,000,000 Initial Public Offering Jul 6, 2026